We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CDC Expert Panel Endorses Pfizer, Moderna Boosters for All Adults

CDC Expert Panel Endorses Pfizer, Moderna Boosters for All Adults

November 22, 2021

Within hours of the FDA authorizing booster doses of the Pfizer and Moderna COVID-19 vaccines for all adults, a Centers for Disease Control and Prevention (CDC) expert panel unanimously supported the decision.

In an 11 to 0 vote, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended that people 18 years and over will be permitted to receive either a Pfizer or Moderna COVID-19 booster vaccine six months after a primary series, based on their individual benefit and risk.

The panel also voted unanimously to recommend that people 50 years and older “should” get a Pfizer or Moderna COVID-19 booster six months following a primary series, lowering the suggested age threshold which previously included individuals 65 years and older (DID, Oct. 22).

Individuals may also “mix and match” boosters from any vaccine maker, provided enough time has passed from their primary series, the panel said.

The advisory committee had previously endorsed the FDA’s revised Emergency Use Authorization (EUA) allowing a booster J&J shot for all adults two months after they received a single-dose regimen, but the Pfizer and Moderna boosters were previously only available to those 18 years and older if they were at high-risk of contracting severe COVID-19 or at high-risk of based on their workplace.

Acting FDA Commissioner Janet Woodcock, in remarks shortly before the ACIP’s Friday meeting, noted that “a single booster dose of either the Moderna or Pfizer-BioNTech COVID-19 vaccine for individuals 18 years of age and older helps to provide continued protection against COVID-19, including the serious consequences that can occur, such as hospitalization and death.”

The expanded authorization of booster shots will fulfill a Biden administration commitment, first announced in August, to provide boosters for every American adult.

The ACIP’s recommendations are headed to CDC Director Rochelle Walensky whose final sign-off is required before the boosters can be given to everyone. She is expected to approve it imminently. — Jason Scott

COVID-19

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • BioVentrix gets Expanded Access Approval for Left Ventricle Support System

  • FDA Approves Stemline’s Orserdu for Several Forms of Breast Cancer

  • FDA Issues Update on LivaNova Recall of Blood Pumping System

  • EU Expands Dupixent’s Authorization to Include Eosinophilic Esophagitis

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing